leadf
logo-loader
viewCalyxt

Calyxt makes change to business model as they look to ramp up go-to-markets strategy

Calyxt (NASDAQ: CLXT) CEO Jim Blome joined Steve Darling from Proactive with the news the company has made some major change in their strategy and business model that set the company up for major growth.

Blome discusses what changes have been made and when investors may see results. Blome also told Proactive about their proprietary gene-editing tool Talen and how they plan on taking it to market.

Quick facts: Calyxt

Price: 3.5 USD

NASDAQ:CLXT
Market: NASDAQ
Market Cap: $129.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Calyxt named herein, including the promotion by the Company of Calyxt in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Strategic Minerals' £700k raise 'clears way for true potential value ahead'

Strategic Minerals PLC's (LON:SML), Peter Wale talks to Proactive London about their £700,000 of which £48,900 was in 'salary sacrifices'. He says they had 'plenty of demand' which supports his view that 'the market price is still very much wrong'. Wale says that this could be their last...

42 minutes ago

2 min read